Effects of pentoxifylline on whole blood IL-2 and IFN-gamma gene expression in normal dogs.
cyclosporine
cytokine
dog
interferon-γ
interleukin-2
lymphocytes
pentoxifylline
Journal
Veterinary medicine and science
ISSN: 2053-1095
Titre abrégé: Vet Med Sci
Pays: England
ID NLM: 101678837
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
29
04
2019
revised:
31
07
2019
accepted:
30
08
2019
pubmed:
18
10
2019
medline:
2
2
2021
entrez:
18
10
2019
Statut:
ppublish
Résumé
Pentoxifylline (PTX) is a methylxanthine phosphodiesterase inhibitor that is used as a hemorrheologic and anti-inflammatory agent in veterinary and human medicine. In human studies, PTX has been shown to decrease T-cell production of cytokines such as IL-2 and IFN-γ. A RT-qPCR assay to measure activated T-cell gene expression of IL-2 and IFN-γ has been validated in dogs. The goal of this study was to utilize this assay to investigate the effects of PTX on in vitro cytokine gene expression in canine whole blood. Whole blood from seven healthy dogs was collected and incubated with various concentrations of PTX for 1 hr before activation. PTX concentrations spanned and exceeded blood concentrations achieved when administered at clinically relevant dosages (1, 2, 10, 50 and 200 μg/ml). Cyclosporine was used at a concentration of 500 ng/ml as a positive control. All blood samples, including untreated activated baseline samples, were then activated with phorbol myristate acetate and ionomycin for 5 hrs. Analysis of activated whole blood by RT-qPCR revealed that there was not a significant suppression of IL-2 or IFN-γ gene expression at any concentration of PTX when evaluating ΔCt values. All samples exposed to cyclosporine showed significant changes from untreated activated baseline samples, demonstrating marked suppression as the positive control. Cytokine expression, presented as a percentage of untreated activated baseline samples, was also evaluated. After exposure to the highest concentration of PTX (200 μg/ml), median percentage cytokine expression was suppressed to just below 50% of baseline values. This concentration, however, is much higher than blood concentrations reported to be achieved at standardly used pentoxifylline doses. PTX does not appear to significantly suppress T-cell cytokine production in samples from most dogs at clinically relevant drug concentrations. Further testing is needed to establish the full effects of PTX on the immune system in dogs.
Sections du résumé
BACKGROUND
Pentoxifylline (PTX) is a methylxanthine phosphodiesterase inhibitor that is used as a hemorrheologic and anti-inflammatory agent in veterinary and human medicine. In human studies, PTX has been shown to decrease T-cell production of cytokines such as IL-2 and IFN-γ. A RT-qPCR assay to measure activated T-cell gene expression of IL-2 and IFN-γ has been validated in dogs.
OBJECTIVES
The goal of this study was to utilize this assay to investigate the effects of PTX on in vitro cytokine gene expression in canine whole blood.
METHODS
Whole blood from seven healthy dogs was collected and incubated with various concentrations of PTX for 1 hr before activation. PTX concentrations spanned and exceeded blood concentrations achieved when administered at clinically relevant dosages (1, 2, 10, 50 and 200 μg/ml). Cyclosporine was used at a concentration of 500 ng/ml as a positive control. All blood samples, including untreated activated baseline samples, were then activated with phorbol myristate acetate and ionomycin for 5 hrs.
RESULTS
Analysis of activated whole blood by RT-qPCR revealed that there was not a significant suppression of IL-2 or IFN-γ gene expression at any concentration of PTX when evaluating ΔCt values. All samples exposed to cyclosporine showed significant changes from untreated activated baseline samples, demonstrating marked suppression as the positive control. Cytokine expression, presented as a percentage of untreated activated baseline samples, was also evaluated. After exposure to the highest concentration of PTX (200 μg/ml), median percentage cytokine expression was suppressed to just below 50% of baseline values. This concentration, however, is much higher than blood concentrations reported to be achieved at standardly used pentoxifylline doses.
CONCLUSIONS
PTX does not appear to significantly suppress T-cell cytokine production in samples from most dogs at clinically relevant drug concentrations. Further testing is needed to establish the full effects of PTX on the immune system in dogs.
Identifiants
pubmed: 31621209
doi: 10.1002/vms3.204
pmc: PMC7036308
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Interleukin-2
0
Phosphodiesterase Inhibitors
0
Interferon-gamma
82115-62-6
Pentoxifylline
SD6QCT3TSU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-24Subventions
Organisme : NIH Clinical Center
ID : 5T35OD010432-14
Pays : International
Informations de copyright
© 2019 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
Références
Iran J Basic Med Sci. 2015 Mar;18(3):247-52
pubmed: 25945237
Vet Ther. 2003 Summer;4(2):188-96
pubmed: 14506595
Immunol Lett. 1993 Aug;37(2-3):131-8
pubmed: 7505000
Immunity. 1997 Feb;6(2):165-74
pubmed: 9047238
J Cardiovasc Pharmacol. 1995;25 Suppl 2:S75-9
pubmed: 8699867
Vet Med Sci. 2020 Feb;6(1):19-24
pubmed: 31621209
J Cardiovasc Pharmacol. 1995;25 Suppl 2:S80-4
pubmed: 8699868
Clin Infect Dis. 2000 Sep;31 Suppl 3:S101-5
pubmed: 11010833
Immunology. 1993 Sep;80(1):151-6
pubmed: 8244458
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Clin Pharmacol. 1998 Jun;38(6):561-6
pubmed: 9650547
J Vet Med Sci. 2007 Sep;69(9):887-92
pubmed: 17917372
J Am Anim Hosp Assoc. 2003 Mar-Apr;39(2):139-50
pubmed: 12617542
Vet Immunol Immunopathol. 2011 Apr 15;140(3-4):175-80
pubmed: 21227512
Blood. 1991 Apr 15;77(8):1653-6
pubmed: 1707692
AIDS. 1996 May;10(5):469-75
pubmed: 8724037
Int J Immunopharmacol. 1995 Dec;17(12):1007-16
pubmed: 8964650
Cancer Immunol Immunother. 1993;36(1):57-60
pubmed: 7678547
Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):331-45
pubmed: 11553396
Am J Vet Res. 2000 Jun;61(6):631-7
pubmed: 10850837
Immunology. 1993 Apr;78(4):520-5
pubmed: 8388363
Vet Immunol Immunopathol. 2013 Dec 15;156(3-4):229-34
pubmed: 24422229
J Am Acad Dermatol. 1994 Apr;30(4):603-21
pubmed: 8157787
J Vet Pharmacol Ther. 2010 Oct;33(5):495-8
pubmed: 20860099